Home/ Stocks/ COAG

Hemab Therapeutics Holdings, Inc. Common Stock

COAG XNAS

$49.02 +3.45 (+7.57%) ▲ 15-min delayed

Open

$46.18

High

$49.12

Low

$45.52

Volume

428.0K

Market Cap

$2.29B

About Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Website →

Related Market News

No specific coverage for COAG yet. Check out our latest market news or earnings calendar.

Get COAG Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Hemab Therapeutics Holdings, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.